NanoVibronix (NASDAQ:NAOV) & Jin Medical International (NASDAQ:ZJYL) Head-To-Head Analysis

Profitability

This table compares Jin Medical International and NanoVibronix’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Jin Medical International	N/A	N/A	N/A
NanoVibronix	-93.80%	-101.17%	-53.03%

Institutional and Insider Ownership

16.4% of NanoVibronix shares are owned by institutional investors. 7.0% of NanoVibronix shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Volatility & Risk

Jin Medical International has a beta of 12.28, indicating that its share price is 1,128% more volatile than the S&P 500. Comparatively, NanoVibronix has a beta of 1.84, indicating that its share price is 84% more volatile than the S&P 500.

Valuation and Earnings

This table compares Jin Medical International and NanoVibronix”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Jin Medical International	$23.50 million	6.26	$3.68 million	N/A	N/A
NanoVibronix	$2.56 million	2.12	-$3.71 million	($13.53)	-0.53

Jin Medical International has higher revenue and earnings than NanoVibronix.

Summary

Jin Medical International beats NanoVibronix on 7 of the 9 factors compared between the two stocks.

About Jin Medical International

Jin Medical International Ltd. engages in the design, development, manufacturing, and sale of wheelchair and other living aids products for people with disabilities or impaired mobility in China and internationally. It also offers oxygen concentrators and bathing machines. The company was founded in 2006 and is based in Changzhou, China. Jin Medical International Ltd. is a subsidiary of Jolly Harmony Enterprises Limited.

About NanoVibronix

NanoVibronix, Inc., through its subsidiary, NanoVibronix Ltd., focuses on the manufacture and sale of noninvasive biological response-activating devices that target biofilm prevention, wound healing, and pain therapy. Its product portfolio includes UroShield, an ultrasound-based product to prevent bacterial colonization and biofilm in urinary catheters, enhance antibiotic efficacy, and decrease pain and discomfort associated with urinary catheter use. The company also offers PainShield, a patch-based therapeutic ultrasound technology to treat pain, muscle spasm, and joint contractures; and WoundShield, a patch-based therapeutic ultrasound device intended to facilitate tissue regeneration and wound healing by using ultrasound to increase local capillary perfusion and tissue oxygenation. It sells its products directly to patients, as well as through distributor agreements in the United States, Israel, Europe, Australia, India, and internationally. The company was incorporated in 2003 and is headquartered in Elmsford, New York.